AbbVie Inc (ABBV.K)

ABBV.K on New York Consolidated

64.51USD
27 Aug 2015
Change (% chg)

-- (--)
Prev Close
$64.51
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
9,393,909
52-wk High
$71.60
52-wk Low
$52.06

ABBV.K

Chart for ABBV.K

About

AbbVie Inc. (AbbVie) is a global, research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company's products are focused on treating conditions, such as chronic autoimmune diseases, including rheumatoid arthritis, psoriasis and Crohn's disease; hepatitis C (HCV);... (more)

Overall

Beta: --
Market Cap(Mil.): $104,514.10
Shares Outstanding(Mil.): 1,655.28
Dividend: 0.51
Yield (%): 3.23

Financials

  ABBV.K Industry Sector
P/E (TTM): 49.39 33.75 34.00
EPS (TTM): 1.28 -- --
ROI: 6.38 15.10 14.57
ROE: 38.87 15.69 15.46
Search Stocks

AbbVie buys special review voucher for $350 million

- AbbVie Inc has bought a priority review voucher from United Therapeutics Corp for $350 million that will allow it to accelerate the review process for one of its drugs.

19 Aug 2015

AbbVie buys special review voucher for $350 mln

Aug 19 - AbbVie Inc has bought a priority review voucher from United Therapeutics Corp for $350 million that will allow it to accelerate the review process for one of its drugs.

19 Aug 2015

UPDATE 2-AbbVie to seek approval for potential blockbuster leukemia drug

Aug 12 - AbbVie Inc on Wednesday said its experimental treatment for a form of leukemia associated with a gene mutation met its main goal in a mid-stage trial and that the company would seek U.S. approval of the medicine, which analysts have said has blockbuster sales potential.

12 Aug 2015

AbbVie to seek approval for potential blockbuster leukemia drug

- AbbVie Inc on Wednesday said its experimental treatment for a form of leukemia associated with a gene mutation met its primary goal in a mid-stage trial and that the company would seek U.S. approval of the medicine, which analysts have said has blockbuster sales potential.

12 Aug 2015

AbbVie to seek FDA approval for leukemia drug after trial success

Aug 12 - AbbVie Inc on Wednesday said its experimental treatment for a form of leukemia associated with a gene mutation met its primary goal in a mid-stage trial and that the company would seek U.S. approval of the medicine, which analysts have said has blockbuster sales potential.

12 Aug 2015

Drugmaker Shire bids $30 billion for Baxter spin-off Baxalta

LONDON - Drugmaker Shire said on Tuesday it was seeking to buy Baxalta , a company spun-off by Baxter International last month, for $30 billion to forge the leading global specialist in rare diseases.

04 Aug 2015

BRIEF-Ablynx initiates phase II SLE study with its anti-IL-6R Nanobody

* Ablynx initiates phase II SLE study with its anti-IL-6R Nanobody, partnered with Abbvie Inc

04 Aug 2015

AbbVie, Bristol-Myers get FDA nod for hep C treatments

- The U.S. Food and Drug Administration on Friday approved two treatments for less common forms of hepatitis C virus (HCV) infections.

24 Jul 2015

CORRECTED-UPDATE 2-AbbVie, Bristol-Myers get FDA nod for hep C treatments

July 24 - The U.S. Food and Drug Administration on Friday approved two treatments for less common forms of hepatitis C virus (HCV) infections.

24 Jul 2015

AbbVie's revenue miss raises concerns over Humira sales

- AbbVie Inc reported quarterly revenue that missed analysts' estimates for the first time in six quarters, sparking concerns over slowing sales growth for its flagship arthritis drug, Humira.

24 Jul 2015

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $96.22 +1.11
Pfizer Inc. (PFE.N) $33.26 +0.83
Novartis AG (NOVN.VX) CHF94.85 +0.50
Merck & Co., Inc. (MRK.N) $54.95 +0.53
Roche Holding Ltd. (ROG.VX) CHF267.60 +0.60
Abbott Laboratories (ABT.N) $45.64 +1.66
Eli Lilly and Co (LLY.N) $83.74 +2.64

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Stock Traders Daily
$20.00
Provider : Thomson Reuters Stock Report
$25.00
Provider : ValuEngine, Inc.
$49.00
Provider : Pechala's Reports
$15.00
Provider : S&P Capital IQ – STARS Reports
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks